You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 284 No. 2, July 12, 2000 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Clinical Investigation
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (44)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •HIV/AIDS
 •Alert me on articles by topic

Failure of Routine HIV-1 Tests in a Case Involving Transmission With Preseroconversion Blood Components During the Infectious Window Period

Ai Ee Ling, MD; Kenneth E. Robbins, BS; Teresa M. Brown, BS; Valerie Dunmire, MS; Su Yun Se Thoe, MSc; Sin-Yew Wong, MD; Yee Sin Leo, MD; Diana Teo, MD; James Gallarda, PhD; Bruce Phelps, PhD; Mary E. Chamberland, MD; Michael P. Busch, MD, PhD; Thomas M. Folks, PhD; Marcia L. Kalish, PhD

JAMA. 2000;284:210-214.

Context  Current screening practices for blood donations have been successful in reducing human immunodeficiency virus (HIV) transmission through receipt of contaminated blood products. However, HIV-infected blood donations made prior to seroconversion and before high levels of viral replication occur could test negative using both serologic antigen and antibody tests. Testing based on nucleic acid amplification (NAT) is being implemented to screen for HIV-infected blood donated during this period, yet the issue of single vs minipool donation screening remains unresolved.

Objectives  To determine HIV-1 genetic linkage between virus in 2 HIV-1–infected recipients of blood components and virus in the donor, who was HIV antigen and antibody negative at the time of donation; to screen the blood donor's plasma with HIV NAT assays, including those currently proposed for use in US blood donation screening.

Design and Setting  Case study conducted in October 1997 involving the Communicable Disease Centre, Singapore General Hospital, and the Singapore Blood Transfusion Service, Singapore.

Subjects  The blood donor and the 2 recipients of donor platelets and red blood cells.

Main Outcome Measures  Genetic analysis of the HIV-1 p17 coding region of gag and the C2V5 region of env to determine the genetic relatedness of virus from the donor and recipients; reactivity in quantitative and qualitative assays, and reactivity in donor screening HIV NAT assays in single donation and minipool screening contexts.

Results  Direct DNA sequencing demonstrated identical HIV-1 subtype E viral sequences in the donor and recipients. Based on comparisons of a qualitative and quantitative assay for HIV-1 RNA levels, a low level of viremia (range, 5-39 copies/mL in plasma) was estimated to be in the donor's undiluted blood at the time of donation. Additional testing using donor-screening NAT assays showed consistent detection of HIV RNA in the undiluted donor plasma whereas detection was inconsistent at the 1:16 and 1:24 dilution levels currently used in minipool screening of blood donations in the United States.

Conclusions  Transmission of HIV from a blood donor to a platelet recipient and a red blood cell recipient occurred in the preseroconversion infectious window period. The viral load in the implicated donation was estimated to be less than 40 copies/mL of plasma. Current US minipool HIV NAT screening protocols may not be sufficiently sensitive to detect all infectious window-period donations.


Author Affiliations: Singapore General Hospital, Singapore (Dr Ling and Ms Se Thoe); Division of AIDS, STD, and TB Laboratory Research (Mr Robbins, Mss Brown and Dunmire, and Drs Folks and Kalish), Division of Viral and Rickettsial Diseases (Dr Chamberland), National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Ga; Communicable Disease Centre, Singapore (Drs Wong and Leo); Singapore Blood Transfusion Service, Singapore (Dr Teo); Roche Molecular Systems, Pleasanton, Calif (Dr Gallarda); Chiron Corporation, Blood Testing Division, Emeryville, Calif (Dr Phelps); and Blood Centers of the Pacific and the University of California, San Francisco, and Blood Systems Inc, Scottsdale, Ariz (Dr Busch).


RELATED ARTICLES

Trends in Incidence and Prevalence of Major Transfusion-Transmissible Viral Infections in US Blood Donors, 1991 to 1996
Simone A. Glynn, Steven H. Kleinman, George B Schreiber, Michael P. Busch, David J. Wright, James W. Smith, Catharie C. Nass, Alan E. Williams, and for the Retrovirus Epidemiology Donor Study
JAMA. 2000;284(2):229-235.
ABSTRACT | FULL TEXT  

Will Blood Transfusion Ever Be Safe Enough?
Harvey G. Klein
JAMA. 2000;284(2):238-240.
EXTRACT | FULL TEXT  

July 12, 2000
JAMA. 2000;284(2):249-250.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Frequency, Causes, and New Challenges of Indeterminate Results in Western Blot Confirmatory Testing for Antibodies to Human Immunodeficiency Virus
Guan
CVI 2007;14:649-659.
FULL TEXT  

Transfusion Safety: Where Are We Today?
LUBAN
Ann. N. Y. Acad. Sci. 2005;1054:325-341.
ABSTRACT | FULL TEXT  

HIV Seroconversion Resulting from Insensitive Blood Screening Measures
JWatch Emergency Med. 2000;2000:1-1.
FULL TEXT  

Safeguarding Blood Against HIV: When Is Enough Enough?
JWatch General 2000;2000:1-1.
FULL TEXT  

Will Blood Transfusion Ever Be Safe Enough?
Klein
JAMA 2000;284:238-240.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.